NCI-2018-01519

S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

This research study is a Phase II randomized, double-blind, placebo-controlled trial that is studying a new treatment for inflammatory breast cancer. The new treatment being studied in S1706 is olaparib, which is a drug that works by blocking a protein called PARP. PARP is involved in repairing DNA damage in cells. By blocking PARP, olaparib can help to kill cancer cells that have mutations in genes involved in DNA repair.The trial is designed to compare the effectiveness of olaparib combined with radiation therapy to radiation therapy alone for patients with inflammatory breast cancer.

Placebo: A placebo is a substance or treatment that has no active medical properties but is given to a patient as if it were a real medication or treatment. It is often used in medical research to compare the effects of a new drug or treatment with the effects of no treatment at all. The idea is to see if the new drug or treatment is genuinely effective by comparing how patients who receive the real treatment fare compared to those who receive the placebo

Double-blind: Neither the patients nor the doctors know who is getting what treatment. This helps make sure the results are completely not biased

Phase II: An advanced point of testing, where they're trying to confirm if a treatment works well.

Randomized: Patients are randomly assigned to one of two groups. It's like flipping a coin to decide who gets which treatment

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT03598257

NCI-2018-01519

Clinical Trial Site: Columbia

To see all available clinical trials click here.